Aliases & Classifications for Dry Eye Syndrome

MalaCards integrated aliases for Dry Eye Syndrome:

Name: Dry Eye Syndrome 12 15
Dry Eye Syndromes 55 44 73
Tear Film Insufficiency 12
Xerophthalmia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10140
ICD10 33 H04.12
MeSH 44 D015352
NCIt 50 C34553
SNOMED-CT 68 46152009

Summaries for Dry Eye Syndrome

MalaCards based summary : Dry Eye Syndrome, also known as dry eye syndromes, is related to keratoconjunctivitis sicca and keratoconjunctivitis, and has symptoms including dryness of eye and dacryops. An important gene associated with Dry Eye Syndrome is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Miconazole and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and thyroid, and related phenotypes are liver/biliary system and vision/eye

Wikipedia : 76 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Dry Eye Syndrome

Diseases related to Dry Eye Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 32.9 TNF TLR9 NGF LTF IL6
2 keratoconjunctivitis 30.1 NGF TLR9 TNF
3 sjogren syndrome 11.6
4 premature ovarian failure 1 11.0
5 scorpion envenomation 10.3 IL6 TNF
6 autoimmune gastritis 10.3 EGF IL6 TNF
7 leukomalacia 10.2 IL6 TNF
8 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
9 fasciitis 10.2 IL6 MUC1 TNF
10 rasmussen encephalitis 10.2 BMP6 IL6 TNF
11 q fever 10.2 ARG1 IL6 TNF
12 laryngitis 10.2 TNF IL6 FGF2
13 critical limb ischemia 10.2 TNF IL6 HGF
14 aggressive periodontitis 10.2 IL6 LTF TNF
15 radiation proctitis 10.2 LTF FGF2 TNF
16 proctitis 10.2 FGF2 LTF TNF
17 streptococcal toxic-shock syndrome 10.2 IL6 TNF
18 obstructive jaundice 10.2 HGF IL6 TNF
19 gingivitis 10.2 IL6 LTF TNF
20 stromal keratitis 10.2 IL6 LCN1 TNF
21 rheumatoid vasculitis 10.2 CD44 LTF TNF
22 cataract 10.2
23 gastric ulcer 10.2 EGF FGF2 HGF
24 central nervous system vasculitis 10.1 IL6 TLR9 TNF
25 autoimmune disease of eyes, ear, nose and throat 10.1 IL6 TLR9 TNF
26 hypersensitivity reaction type iii disease 10.1 IL6 TLR9 TNF
27 rheumatoid arthritis 10.1
28 arthritis 10.1
29 allergic conjunctivitis 10.1
30 conjunctivitis 10.1
31 limb ischemia 10.1 TNF IL6 HGF FGF2
32 exanthem 10.1 IL6 TLR9 TNF
33 extrinsic cardiomyopathy 10.1 IL6 TLR9 TNF
34 lymph node disease 10.1 IL6 TLR9 TNF
35 uveal disease 10.1 IL6 TLR9 TNF
36 pulmonary edema 10.1 AQP5 FGF7 TNF
37 human immunodeficiency virus infectious disease 10.1 IL6 TLR9 TNF
38 juvenile ankylosing spondylitis 10.1 IL6 TNF
39 tonsillitis 10.1 IL6 TLR9 TNF
40 parasitic protozoa infectious disease 10.1 IL6 TLR9 TNF
41 filariasis 10.1 IL6 TLR9 TNF
42 familial progressive hyperpigmentation 10.1 FGF7 HGF
43 autoimmune disease of musculoskeletal system 10.1 IL6 TLR9 TNF
44 periodontitis 10.1 IL6 TLR9 TNF
45 bacterial meningitis 10.1 IL6 TLR9 TNF
46 eye lymphoma 10.1 IL6 TLR9
47 meningitis 10.1 IL6 TLR9 TNF
48 primary bacterial infectious disease 10.1 IL6 TLR9 TNF
49 bacterial infectious disease 10.1 IL6 TLR9 TNF
50 juvenile nasopharyngeal angiofibroma 10.1 BMP6 FGF2 TLR9

Graphical network of the top 20 diseases related to Dry Eye Syndrome:



Diseases related to Dry Eye Syndrome

Symptoms & Phenotypes for Dry Eye Syndrome

UMLS symptoms related to Dry Eye Syndrome:


dryness of eye, dacryops

MGI Mouse Phenotypes related to Dry Eye Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.5 ARG1 CD44 HGF IL6 LTF TNF
2 vision/eye MP:0005391 9.23 AQP5 CD44 EGF FGF2 FGF7 IL6

Drugs & Therapeutics for Dry Eye Syndrome

Drugs for Dry Eye Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 376)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
3
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
4
Povidone Approved Phase 4,Not Applicable 9003-39-8
5
Dipivefrin Approved Phase 4,Phase 3,Phase 1,Not Applicable 52365-63-6 3105
6
Ephedrine Approved Phase 4 299-42-3 9294
7
Pseudoephedrine Approved Phase 4 90-82-4 7028
8
Travoprost Approved Phase 4 157283-68-6 5282226
9
Calcium Carbonate Approved, Investigational Phase 4 471-34-1
10
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
11
Prednisone Approved, Vet_approved Phase 4,Phase 1 53-03-2 5865
12
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 56-81-5 753
13
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 9865442 444025
14
Tobramycin Approved, Investigational Phase 4,Phase 1,Not Applicable 32986-56-4 36294 5496
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
16
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
17 Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
18
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
19
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
20
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6
21
Menthol Approved Phase 4 2216-51-5 16666
22
Tacrolimus Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
23
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1 302-25-0
24
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 50-24-8 5755
25
Ofloxacin Approved Phase 4 82419-36-1 4583
26
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
27
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1 2921-57-5
28
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1 83-43-2 6741
29
Azithromycin Approved Phase 4 83905-01-5 55185 447043
30
Ketorolac Approved Phase 4,Phase 2 66635-83-4, 74103-06-3 3826
31
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
32
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
33
Dimenhydrinate Approved Phase 4,Not Applicable 523-87-5 441281
34
Latanoprost Approved, Investigational Phase 4,Phase 3,Not Applicable 130209-82-4 5311221 5282380
35
Pilocarpine Approved, Investigational Phase 4 54-71-7, 92-13-7 5910
36
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
37
Sulfacetamide Approved Phase 4 144-80-9 5320
38
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
39
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
40
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
41
Doxazosin Approved Phase 4 74191-85-8 3157
42
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
43
Oxybutynin Approved, Investigational Phase 4,Not Applicable 5633-20-5 4634
44
Allantoin Approved Phase 4,Not Applicable 97-59-6 204
45 sodium fluoride Approved Phase 4,Not Applicable 7681-49-4
46
Sorbitol Approved Phase 4,Not Applicable 50-70-4 5780
47 tannic acid Approved Phase 4,Not Applicable
48
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
49
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
50
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963

Interventional clinical trials:

(show top 50) (show all 868)
# Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
3 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
4 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
8 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
9 Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease Unknown status NCT01738243 Phase 4 Hyaluronic Acid Gel injection;Saline injection
10 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
11 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
12 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
13 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
14 The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome Completed NCT03666884 Phase 4 COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
15 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
16 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
17 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
18 Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms Completed NCT03451396 Phase 4 Lifitegrast
19 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
20 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
21 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
22 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
23 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
24 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
25 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
26 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
27 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
28 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
29 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
30 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
31 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
32 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
33 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
34 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
35 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
36 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
37 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
38 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
39 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
40 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
41 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
42 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
43 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
44 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
45 Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye Completed NCT01684436 Phase 4
46 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
47 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
48 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
49 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%
50 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops

Search NIH Clinical Center for Dry Eye Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: dry eye syndromes

Genetic Tests for Dry Eye Syndrome

Anatomical Context for Dry Eye Syndrome

MalaCards organs/tissues related to Dry Eye Syndrome:

41
Eye, Testes, Thyroid, Skin, Bone, Liver, Lymph Node

Publications for Dry Eye Syndrome

Articles related to Dry Eye Syndrome:

(show top 50) (show all 333)
# Title Authors Year
1
Outcomes of Thermal Pulsation Treatment for Dry Eye Syndrome in Patients With Sjogren Disease. ( 29708939 )
2018
2
Feline dry eye syndrome of presumed neurogenic origin: a case report. ( 29318025 )
2018
3
Optimizing acupuncture treatment for dry eye syndrome: a systematic review. ( 29724255 )
2018
4
Micro-instillation of fluorescein with an inoculation loop for ocular surface staining in dry eye syndrome. ( 29068175 )
2018
5
Dry eye syndrome: developments and lifitegrast in perspective. ( 29391773 )
2018
6
Reflections on Dry Eye Syndrome Treatment: Therapeutic Role of Blood Products. ( 29527528 )
2018
7
The Correlation between Daily Lens Wear Duration and Dry Eye Syndrome. ( 29875854 )
2018
8
Dry Eye Syndrome in Intensive Care Units: a concept analysis. ( 29924155 )
2018
9
Dry eye syndrome and the subsequent risk of chronic fatigue syndrome-a prospective population-based study in Taiwan. ( 30093979 )
2018
10
Relationship between Dry Eye Syndrome and Frequency of Coffee Consumption in Korean Adults: Korea National Health and Nutrition Examination Survey V, 2010-2012. ( 30049179 )
2018
11
Effect of 5-Oxo-2-Pyrrolidinecarboxylic Acid (PCA) as a New Topically Applied Agent for Dry Eye Syndrome Treatment. ( 30149648 )
2018
12
Assessment of visual function and Vision-related Quality of Life in female contact lens wearers with Dry Eye Syndrome. ( 30224885 )
2018
13
Combination of recurrent oral aphthae and dry eye syndrome may constitute an independent risk factor for oral cavity cancer in elderly women. ( 30233243 )
2018
14
The Effect of Artificial Tear Preparations with Three Different Ingredients on Contrast Sensitivity in Patients with Dry Eye Syndrome. ( 30250858 )
2018
15
Sex hormone therapy's effect on dry eye syndrome in postmenopausal women: A meta-analysis of randomized controlled trials. ( 30290618 )
2018
16
An Automated Grading and Diagnosis System for Evaluation of Dry Eye Syndrome. ( 30298212 )
2018
17
Potentiality of microemulsion systems in treatment of ophthalmic disorders: Keratoconus and dry eye syndrome - In vivo study. ( 30300828 )
2018
18
Effect of Single Instillation of Two Hyaluronic Acid-Based Topical Lubricants on Tear Film Thickness in Patients with Dry Eye Syndrome. ( 30325687 )
2018
19
Punctal occlusion for dry eye syndrome: summary of a Cochrane systematic review. ( 30337332 )
2018
20
Dry Eye Syndrome Preferred Practice Pattern®. ( 30366798 )
2018
21
Osteoporosis and dry eye syndrome: A previously unappreciated association that may alert active prevention of fall. ( 30395639 )
2018
22
Cross-linked hyaluronic acid gel occlusive device for the treatment of dry eye syndrome. ( 30510396 )
2018
23
Gelatin-epigallocatechin gallate nanoparticles with hyaluronic acid decoration as eye drops can treat rabbit dry-eye syndrome effectively via inflammatory relief. ( 30510416 )
2018
24
Air pollutant particulate matter 2.5 induces dry eye syndrome in mice. ( 30546125 )
2018
25
Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome. ( 30025146 )
2018
26
Magnitude of diabetes and hypertension among patients with Dry Eye Syndrome at a tertiary hospital of Riyadh, Saudi Arabia - A case series. ( 28559720 )
2017
27
Autologous artificial tears used for treatment of dry eye syndrome in patients with chronic graft versus host disease. ( 29162791 )
2017
28
Aqueous Deficient Dry Eye Syndrome Post Orbital Radiotherapy: A 10-Year Retrospective Study. ( 28660094 )
2017
29
Protective effects of carbenoxolone, an 11I^-HSD1 inhibitor, against chemical induced dry eye syndrome. ( 28887719 )
2017
30
Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. ( 28827614 )
2017
31
Dry Eye Syndrome ( 29262012 )
2017
32
Punctal occlusion for dry eye syndrome. ( 28649802 )
2017
33
Epigallocatechin Gallate-Loaded Gelatin-g-Poly(N-Isopropylacrylamide) as a New Ophthalmic Pharmaceutical Formulation for Topical Use in the Treatment of Dry Eye Syndrome. ( 28839279 )
2017
34
Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial. ( 28367524 )
2017
35
Fingerprick autologous blood: a novel treatment for dry eye syndrome. ( 28622325 )
2017
36
Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. ( 28771187 )
2017
37
Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome. ( 29158874 )
2017
38
Efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids in dry eye syndrome: a systematic review of randomized clinical trials. ( 28371493 )
2017
39
Aging eye microbiota in Dry Eye Syndrome in patients treated with Enterococcus faecium and Saccharomyces boulardii. ( 28676009 )
2017
40
Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study. ( 28752695 )
2017
41
The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. ( 28910552 )
2017
42
Dry Eye Syndrome in Menopause and Perimenopausal Age Group. ( 28706404 )
2017
43
Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome. ( 28487505 )
2017
44
Tear Fluid Protein Changes in Dry Eye Syndrome Associated with Rheumatoid Arthritis: A Proteomic Approach. ( 27789276 )
2017
45
Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome. ( 28759302 )
2017
46
A Prospective, Randomized Trial of Two Mucin Secretogogues for the Treatment of Dry Eye Syndrome in Office Workers. ( 29123104 )
2017
47
Evaluation of Decellularized Porcine Jejunum as a Matrix for Lacrimal Gland Reconstruction In Vitro for Treatment of Dry Eye Syndrome. ( 29079859 )
2017
48
Therapeutic inhibitors for the treatment of dry eye syndrome. ( 29115899 )
2017
49
Risk of dry eye syndrome in patients treated with whole-brain radiotherapy. ( 28784430 )
2017
50
Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome. ( 28643798 )
2017

Variations for Dry Eye Syndrome

Expression for Dry Eye Syndrome

Search GEO for disease gene expression data for Dry Eye Syndrome.

Pathways for Dry Eye Syndrome

Pathways related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 ARG1 CD44 EGF FGF2 FGF7 HGF
2
Show member pathways
13.51 BMP6 EGF FGF2 FGF7 HGF IL6
3
Show member pathways
13.32 CD44 EGF FGF2 FGF7 HGF IL6
4
Show member pathways
13.32 BMP6 EGF FGF2 FGF7 HGF IL6
5
Show member pathways
13.28 BMP6 EGF FGF2 FGF7 HGF IL6
6
Show member pathways
13.26 BMP6 EGF FGF2 FGF7 HGF IL6
7
Show member pathways
13.2 AQP5 BMP6 EGF FGF2 FGF7 HGF
8
Show member pathways
13.02 BMP6 EGF FGF2 FGF7 HGF IL6
9
Show member pathways
13 BMP6 EGF FGF2 FGF7 HGF IL6
10
Show member pathways
12.93 EGF FGF2 FGF7 HGF IL6 NGF
11 12.79 EGF FGF2 FGF7 HGF IL6
12
Show member pathways
12.73 EGF FGF2 FGF7 HGF IL6
13 12.71 EGF FGF2 FGF7 HGF NGF TNF
14
Show member pathways
12.69 EGF FGF2 FGF7 HGF NGF
15
Show member pathways
12.27 BMP6 EGF FGF2 FGF7 HGF IL6
16 12.25 CD44 FGF2 HGF TNF
17
Show member pathways
12.23 BMP6 EGF FGF2 FGF7 HGF IL6
18
Show member pathways
12.15 IL6 MUC1 TLR9 TNF
19 12.15 EGF IL6 TLR9 TNF
20
Show member pathways
12.08 BMP6 FGF2 FGF7 HGF IL6 NGF
21 11.98 EGF FGF2 FGF7 HGF IL6
22
Show member pathways
11.93 BMP6 EGF FGF2 FGF7 HGF IL6
23 11.86 FGF2 HGF IL6 MUC1 TNF
24 11.84 CD44 IL6 TNF
25 11.83 ARG1 IL6 TNF
26 11.74 CD44 EGF FGF2 NGF
27 11.71 IL6 TLR9 TNF
28 11.68 ARG1 IL6 TNF
29 11.52 FGF7 IL6 TNF
30 11.5 HGF IL6 TLR9 TNF
31 11.46 EGF FGF2 HGF IL6
32 11.42 EGF FGF2 FGF7
33 11.4 AQP5 EGF HGF
34 11.39 BMP6 EGF FGF2 FGF7 HGF IL6
35 11.33 IL6 TLR9 TNF
36 11.17 BMP6 HGF IL6 TNF
37 10.9 EGF FGF2 FGF7 HGF IL6 TNF
38 10.76 BMP6 EGF FGF2 FGF7 HGF IL6

GO Terms for Dry Eye Syndrome

Cellular components related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 ARG1 BMP6 EGF FGF2 HGF IL6
2 extracellular region GO:0005576 9.55 ARG1 BMP6 EGF FGF2 FGF7 HGF
3 platelet alpha granule lumen GO:0031093 9.43 EGF HGF ORM1
4 specific granule lumen GO:0035580 9.33 ARG1 LTF ORM1

Biological processes related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.92 FGF2 HGF IL6 MUC1 TNF
2 peptidyl-tyrosine phosphorylation GO:0018108 9.89 EGF FGF2 FGF7 HGF
3 defense response to bacterium GO:0042742 9.88 LACRT LTF S100A8 TLR9 TNF
4 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 NGF S100A8 TNF
5 defense response to Gram-negative bacterium GO:0050829 9.85 IL6 LTF TLR9
6 MAPK cascade GO:0000165 9.85 EGF FGF2 FGF7 HGF TNF
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 CD44 IL6 TNF
8 positive regulation of inflammatory response GO:0050729 9.84 S100A8 TLR9 TNF
9 positive regulation of endothelial cell proliferation GO:0001938 9.82 ARG1 BMP6 FGF2
10 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.81 CD44 HGF NGF
11 response to glucocorticoid GO:0051384 9.81 BMP6 IL6 TNF
12 activation of MAPK activity GO:0000187 9.81 EGF FGF2 HGF TNF
13 positive regulation of epithelial cell proliferation GO:0050679 9.8 BMP6 FGF7 LACRT
14 phosphatidylinositol phosphorylation GO:0046854 9.8 EGF FGF2 FGF7 HGF
15 positive regulation of protein kinase B signaling GO:0051897 9.8 EGF FGF2 FGF7 HGF TNF
16 positive regulation of MAP kinase activity GO:0043406 9.79 EGF FGF2 TNF
17 positive regulation of interleukin-6 production GO:0032755 9.79 IL6 TLR9 TNF
18 humoral immune response GO:0006959 9.78 IL6 LTF TNF
19 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.76 FGF2 FGF7 TLR9
20 regulation of signaling receptor activity GO:0010469 9.76 BMP6 FGF2 FGF7 HGF IL6 LACRT
21 positive chemotaxis GO:0050918 9.75 FGF2 FGF7 HGF
22 retina homeostasis GO:0001895 9.73 LCN1 LTF PRR4
23 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.72 IL6 LTF S100A8 TLR9 TNF
24 positive regulation of DNA biosynthetic process GO:2000573 9.68 FGF2 HGF
25 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.68 CD44 TNF
26 positive regulation of osteoblast differentiation GO:0045669 9.67 BMP6 HGF IL6 LTF
27 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.66 LACRT LTF
28 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.65 TLR9 TNF
29 negative regulation of lipid storage GO:0010888 9.64 IL6 TNF
30 positive regulation of chemokine production GO:0032722 9.61 IL6 TLR9 TNF
31 positive regulation of neuroinflammatory response GO:0150078 9.6 IL6 TNF
32 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.57 FGF7 HGF
33 negative regulation of interleukin-6 production GO:0032715 9.56 HGF ORM1 TLR9 TNF
34 inflammatory response GO:0006954 9.56 BMP6 CD44 IL6 ORM1 S100A8 TLR9
35 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.1 CD44 EGF FGF7 HGF IL6 LACRT
36 neutrophil degranulation GO:0043312 10.05 ARG1 CD44 LTF ORM1 S100A8
37 positive regulation of gene expression GO:0010628 10.03 EGF IL6 NGF TLR9 TNF
38 negative regulation of apoptotic process GO:0043066 10.02 CD44 HGF IL6 LACRT LTF NGF
39 positive regulation of cell proliferation GO:0008284 10.01 BMP6 EGF FGF2 FGF7 IL6 LACRT

Molecular functions related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.71 BMP6 FGF2 IL6 TNF
2 protein tyrosine kinase activity GO:0004713 9.67 EGF FGF2 FGF7 HGF
3 1-phosphatidylinositol-3-kinase activity GO:0016303 9.5 FGF2 FGF7 TLR9
4 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.46 EGF FGF2 FGF7 HGF
5 chemoattractant activity GO:0042056 9.43 FGF2 FGF7 HGF
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGF FGF2 FGF7 HGF
7 growth factor activity GO:0008083 9.23 BMP6 EGF FGF2 FGF7 HGF IL6

Sources for Dry Eye Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....